CN102365296A - 用于生成抗体混合物的方法 - Google Patents

用于生成抗体混合物的方法 Download PDF

Info

Publication number
CN102365296A
CN102365296A CN2010800137659A CN201080013765A CN102365296A CN 102365296 A CN102365296 A CN 102365296A CN 2010800137659 A CN2010800137659 A CN 2010800137659A CN 201080013765 A CN201080013765 A CN 201080013765A CN 102365296 A CN102365296 A CN 102365296A
Authority
CN
China
Prior art keywords
replaced
region
nucleic acid
heavy chain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800137659A
Other languages
English (en)
Chinese (zh)
Inventor
P.帕伦
J.J.尼杰森
A.F.拉布里杰恩
J.舒尔曼
T.文克
J.范德温克尔
S.洛夫里克斯
I.拉斯特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of CN102365296A publication Critical patent/CN102365296A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800137659A 2009-01-26 2010-01-26 用于生成抗体混合物的方法 Pending CN102365296A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900118 2009-01-26
DKPA200900118 2009-01-26
PCT/EP2010/050822 WO2010084197A1 (en) 2009-01-26 2010-01-26 Methods for producing mixtures of antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410421605.8A Division CN104262483A (zh) 2009-01-26 2010-01-26 用于生成抗体混合物的方法

Publications (1)

Publication Number Publication Date
CN102365296A true CN102365296A (zh) 2012-02-29

Family

ID=42060888

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800137659A Pending CN102365296A (zh) 2009-01-26 2010-01-26 用于生成抗体混合物的方法
CN201410421605.8A Pending CN104262483A (zh) 2009-01-26 2010-01-26 用于生成抗体混合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410421605.8A Pending CN104262483A (zh) 2009-01-26 2010-01-26 用于生成抗体混合物的方法

Country Status (6)

Country Link
US (1) US20120020952A1 (enExample)
EP (1) EP2389392A1 (enExample)
JP (2) JP2012515540A (enExample)
CN (2) CN102365296A (enExample)
SG (1) SG172977A1 (enExample)
WO (1) WO2010084197A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851338A (zh) * 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN104520319A (zh) * 2012-04-20 2015-04-15 莫鲁斯有限公司 用于产生免疫球蛋白样分子的方法和手段

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
EP3153524B1 (en) * 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN101983968B (zh) * 2010-09-26 2013-03-06 浙江海洋学院 乌贼墨寡肽的酶解制备方法
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
JP6031735B2 (ja) * 2011-06-13 2016-11-24 ソニー株式会社 情報処理装置、情報処理方法およびコンピュータプログラム
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
SI3110849T1 (sl) 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
SG11201609207SA (en) * 2014-05-13 2016-12-29 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
EP3345928B1 (en) 2015-07-10 2020-06-24 Merus N.V. Human cd3 binding antibody
BR112018008068A2 (en) 2015-10-23 2018-11-13 Merus N.V. binding molecules that inhibit cancer growth
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CA3058343A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
HUE071182T2 (hu) 2017-08-09 2025-08-28 Merus Nv EGFR és CMET kötõ antitestek
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668636A (zh) * 2002-07-18 2005-09-14 克鲁塞尔荷兰公司 抗体混合物的重组生产
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
EP1565553A4 (en) * 2002-10-09 2007-11-07 Integrigen Inc RECOMBINANT CATALYTIC POLYPEPTIDES AND USES THEREOF
PT2235064E (pt) * 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668636A (zh) * 2002-07-18 2005-09-14 克鲁塞尔荷兰公司 抗体混合物的重组生产
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104520319A (zh) * 2012-04-20 2015-04-15 莫鲁斯有限公司 用于产生免疫球蛋白样分子的方法和手段
CN104520320A (zh) * 2012-04-20 2015-04-15 莫鲁斯有限公司 用于产生免疫球蛋白样分子的方法和手段
CN104520319B (zh) * 2012-04-20 2017-08-25 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN107383197A (zh) * 2012-04-20 2017-11-24 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN104520320B (zh) * 2012-04-20 2018-05-01 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN107383197B (zh) * 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN114163530A (zh) * 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN102851338A (zh) * 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法

Also Published As

Publication number Publication date
CN104262483A (zh) 2015-01-07
EP2389392A1 (en) 2011-11-30
US20120020952A1 (en) 2012-01-26
JP2016165285A (ja) 2016-09-15
WO2010084197A1 (en) 2010-07-29
JP2012515540A (ja) 2012-07-12
SG172977A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
CN102365296A (zh) 用于生成抗体混合物的方法
US20230303689A1 (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
US20230279117A1 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
TWI841790B (zh) 靶向cd3的抗體、雙特異性抗體及其用途
WO2008145137A2 (en) Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
KR20180030662A (ko) Cd79에 결합하는 항체 분자
JP7620780B2 (ja) Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
KR102571012B1 (ko) 항-il-22r 항체
JP2024531900A (ja) 新規の抗ｓｉｒｐａ抗体
AU2023304358A1 (en) Methods and compositions for treating autoimmune, allergic and inflammatory diseases
US20230374148A1 (en) Binding molecules that multimerise cd45
CN101370526B (zh) 重组单价抗体及其制备方法
AU2017200199B2 (en) Recombinant monovalent antibodies and methods for production thereof
JP7790754B2 (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
WO2025151607A1 (en) Methods and compositions for treating autoimmune, allergic and inflammatory diseases
Zettlitz Engineered antibodies for the therapy of cancer and inflammatory diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120229